Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation

Current Opinion in Cell Biology

Volumn 10, Issue 5, 1998, Pages 667-671

  Johnsen, Morten ^a   Lund, Leif R ^b   Rømer, John ^c   Almholt, Kasper ^b   Danø, Keld ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; BREAST CANCER; BREAST DISEASE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL INTERACTION; CELL TYPE; COLON CANCER; EXTRACELLULAR MATRIX; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SQUAMOUS CELL CARCINOMA; STROMA CELL; WOUND HEALING;

ANIMALIA;

EID: 0031719897     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80044-6     Document Type: Article

References (44)

1. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8:1994;189-203.
2. Sternlicht MD, Werb Z: Extracellular matrix proteinases. In Guidebook to the Extracellular Matrix and Adhesion Proteins. Edited by Kreis T, Vale R. New York: Oxford University Press; in press.
3. Danø K, Grøndahl-Hansen J, Eriksen J, Nielsen BS, Rømer J, Pyke C. The receptor for urokinase plasminogen activator. Stromal cell involvement in extracellular proteolysis during cancer invasion. Barrett AJ, Bond J. Proteolysis and Protein Turnover. 1993;239-245 Portland Press, London.
4. Lund LR, Eriksen J, Ralfkiær E, Rømer J. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester. J Invest Dermatol. 106:1996;622-630.
5. Grøndahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelization in vivo. J Invest Dermatol. 90:1988;790-795.
6. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol. 102:1994;519-522.
7. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 2:1996;287-292.
8. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:1995;794-807.
9. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJS, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 87:1996;709-719.
10. Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol. 135:1996;52-59.
11. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD. Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest. 88:1991;1073-1079.
12. Pyke C, Ralfkiær E, Huhtala P, Hurskainen T, Danø K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 52:1992;1336-1341.
13. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol. 109:1997;225-231.
14. Grigioni WF, D'Errico A, Fiorentino M, Baccarini P, Onisto M, Caenazzo C, Stetler-Stevenson WG, Garbisa S, Mancini AM. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn Mol Pathol. 3:1994;163-169.
15. Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat. 24:1993;185-193.
16. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56:1996;3597-3604.
17. Schuster V, Mingers AM, Seidenspinner S, Nussgens Z, Pukrop T, Kreth HW. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. of outstanding interest Blood. 90:1997;958-966 This paper shows that lack of plasminogen activity in humans is compatible with fetal development and at least childhood life. After the publication of this paper, the clinical manifestation ligneous conjunctivitis was also found in plasminogen-deficient mice (Drew AF: Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998, 91:1616-1624).
18. Schott D, Dempfle CE, Lierman A, Beck P, Kramer MD, Liesenhoff H, Niessen KH, Mohr-Pennert A, Schwartz HP. Homozygous plasminogen-deficiency-treatment and prevention of blindness by long-term replacement therapy with lys-plasminogen [abstract]. Ann Hematol. 72:1997;85. (suppl 2).
19. Mingers AM, Heimburger N, Zeller P, Kreth HW, Schuster V. Homozygous type I plasminogen deficiency. Semin Thromb Hemost. 23:1997;259-264.
20. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brünner N, Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 53:1993;1911-1915.
21. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest. 74:1996;168-177.
22. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 149:1996;273-282.
23. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA. 90:1993;1843-1847.
24. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Danø K. Expression of the matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest. 77:1997;345-355.
25. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 12:1992;954-961.
26. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmbäck K, Drew AF, Flick MJ, Witte DP, Danø K, Degen JL. Reduced metastasis of mammary cancer in plasminogen-deficient mice. of outstanding interest Oncogene. 16:1998;3097-3104 This is the first study that shows that plasminogen has an important function in metastasis. The tumor spread from a primary tumor of genetic origin is significantly delayed in plasminogen-deficient mice. In this tumor model, as in human ductal breast carinomas, urokinase plasminogen activator (uPA) is synthesized by stromal cells.
27. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 140:1998;1535-1541.
28. Sympson CJ, Bissell MJ, Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol. 6:1995;159-163.
29. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 75:1997;69-75.
30. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodeling during mouse mammary gland involution. Development. 115:1992;49-58.
31. Lund LR, Rømer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Danø K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development. 122:1996;181-193.
32. Lefebvre O, Wolf C, Limacher JM, Hutin P, Wendling C, LeMeur M, Basset P, Rio MC. The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J Cell Biol. 119:1992;997-1002.
33. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Amer J Pathol. 138:1991;111-117.
34. Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Amer J Pathol. 138:1991;1059-1067.
35. Pyke C, Ralfkiær E, Rønne E, Høyer-Hansen G, Kirkeby L, Danø K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathol. 24:1994;131-138.
36. Hewitt R, Danø K. Stromal cell expression of components of matrix-degrading protease systems in human cancer. Enzyme Protein. 49:1996;163-173.
37. Larsson L-I, Skriver L, Nielsen LS, Grøndahl-Hansen J, Kristensen P, Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol. 98:1984;894-903.
38. Kristensen P, Eriksen J, Blasi F, Danø K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol. 115:1991;1763-1771.
39. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. of special interest Cancer Res. 58:1998;1048-1051 Two transplanted tumors (Lewis lung carcinoma and B16 melanoma) both show significantly less metastasis to the lungs in matrix metalloproteinase (MMP)-2-deficient mice. As the cancer cells themselves have a fully functional MMP-2 gene, this result points to an important role for host cells as suppliers of MMP-2 activity.
40. Nöel A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle J-M, Remacle A, Kebers F, Brown P, Calberg-Bacq C-M, Foidart J-M. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer. 76:1998;267-273.
41. Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat. 1998;. in press.
42. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:1993;2513-2521.
43. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1:1995;1079-1087.
44. Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, Cardiff RD, Graham FL, Hassell JA, Muller WJ. Requirement for both SHC and phosphatidylinositol 3¢ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. of special interest Mol Cell Biol. 18:1998;2344-2359 A molecular dissection of a mouse tumor model. Mice were made to express mutant alleles of polyoma middle T-antigen (PymT) with known biochemical defects, and the resulting changes in tumor development were characterized.